Form 4 Filing for Emergent BioSolutions Inc.

This filing details a Form 4 filed by Richard S. Lindahl, EVP and Chief Financial Officer of Emergent BioSolutions Inc. On April 29, 2026, Lindahl acquired 162,680 shares of Common Stock at a price of $0.0 per share. This acquisition was part of a restricted stock unit grant approved by the Compensation Committee and subsequently by the Company's stockholders. The restricted stock units vest in three annual installments, with each unit representing the right to receive one share of common stock, subject to continued service. Following this transaction, Lindahl owns 378,047 shares of Emergent BioSolutions Inc. common stock. The transaction code "A" indicates an acquisition, and the $0.0 price suggests it was a grant or award rather than an open market purchase. The filing also notes that the grant was contingent on stockholder approval of an amendment to the Company's 2006 Stock Incentive Plan.